News by Tag: Monoclonal Antibodies
Biotech Growth to Slow Down in the US
March 18, 2013
Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period.
March 18, 2013
Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period.
IMARC Group Releases the Most Comprehensive Report on the Global Biopharmaceutical Market
November 27, 2012
Driven by their target oriented nature that enables them to attack only the diseased cells without affecting the healthy ones, biopharmaceuticals today represent one of the fastest growing segments of the pharmaceutical industry.
November 27, 2012
Driven by their target oriented nature that enables them to attack only the diseased cells without affecting the healthy ones, biopharmaceuticals today represent one of the fastest growing segments of the pharmaceutical industry.
Biologics to Account for 13.5% of the Global Pharmaceutical Market in 2012
November 19, 2012
The global sales of biologics is expected to grow at 8.2 percent compared to 2011, exceeding values worth US$ 117 billion by the end of 2012.
November 19, 2012
The global sales of biologics is expected to grow at 8.2 percent compared to 2011, exceeding values worth US$ 117 billion by the end of 2012.
The Market for Biopharmaceuticals was Worth USD 101 Billion in 2010
August 1, 2011
A new report from IMARC Group expects that driven by factors such as a strong pipeline and ability to treat diseases with high unmet needs, the global market for biopharmaceuticals is expected to reach revenues worth US$ 167 Billion by 2015.
August 1, 2011
A new report from IMARC Group expects that driven by factors such as a strong pipeline and ability to treat diseases with high unmet needs, the global market for biopharmaceuticals is expected to reach revenues worth US$ 167 Billion by 2015.
Emerging Biopharmaceutical Markets to Exceed US$ 13.6 Billion by 2015
June 14, 2011
IMARC Group, one of the world's leading research and advisory firms, finds that the sales of Biopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 to US$ 13.5 Billion in 2015.
June 14, 2011
IMARC Group, one of the world's leading research and advisory firms, finds that the sales of Biopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 to US$ 13.5 Billion in 2015.